AU4510001A - Treatment of inflammatory bowel disease with vitamin d compounds - Google Patents

Treatment of inflammatory bowel disease with vitamin d compounds Download PDF

Info

Publication number
AU4510001A
AU4510001A AU45100/01A AU4510001A AU4510001A AU 4510001 A AU4510001 A AU 4510001A AU 45100/01 A AU45100/01 A AU 45100/01A AU 4510001 A AU4510001 A AU 4510001A AU 4510001 A AU4510001 A AU 4510001A
Authority
AU
Australia
Prior art keywords
vitamin
compound
group
hydroxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45100/01A
Other languages
English (en)
Inventor
Margherita T. Cantorna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of AU4510001A publication Critical patent/AU4510001A/en
Priority to AU2005225056A priority Critical patent/AU2005225056A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU45100/01A 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds Abandoned AU4510001A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005225056A AU2005225056A1 (en) 1999-12-02 2005-10-19 Treatment of inflammatory bowel disease with Vitamin D compounds

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US16850199P 1999-12-02 1999-12-02
US60168501 1999-12-02
US19782700P 2000-04-14 2000-04-14
US60197827 2000-04-14
US20863200P 2000-06-01 2000-06-01
US60208632 2000-06-01
US23190600P 2000-09-11 2000-09-11
US60231906 2000-09-11
PCT/US2000/042393 WO2001042205A2 (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005225056A Division AU2005225056A1 (en) 1999-12-02 2005-10-19 Treatment of inflammatory bowel disease with Vitamin D compounds

Publications (1)

Publication Number Publication Date
AU4510001A true AU4510001A (en) 2001-06-18

Family

ID=27496796

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45100/01A Abandoned AU4510001A (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds

Country Status (5)

Country Link
EP (1) EP1233942A2 (de)
JP (1) JP2003516386A (de)
AU (1) AU4510001A (de)
CA (1) CA2390859A1 (de)
WO (1) WO2001042205A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781113B2 (en) * 1999-12-21 2005-05-05 Wisconsin Alumni Research Foundation Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
JP6114292B2 (ja) * 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用
JP6397695B2 (ja) * 2014-08-25 2018-09-26 学校法人自治医科大学 抗ピロリ菌剤
US9688596B2 (en) * 2015-08-05 2017-06-27 Wisconsin Alumni Research Foundation Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds
EP4117454A4 (de) * 2020-02-11 2024-06-12 The E. Wolfson Medical Center Wirksames verfahren zur behandlung von colitis ulcerosa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2543627B2 (ja) * 1990-02-09 1996-10-16 帝人株式会社 活性型ビタミンｄ含有治療剤
DE4221961A1 (de) * 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag History of 52-carboxylic acid, processes for their preparation and pharmaceutical preparations containing them
DE4405545A1 (de) * 1994-02-22 1995-08-31 Dietl Hans Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
JP2002506429A (ja) * 1997-05-16 2002-02-26 ウィメン アンド インファンツ ホスピタル ３−エピビタミンｄ２化合物及びその使用法
DE69832699T2 (de) * 1997-05-16 2006-08-24 Woman & Infants Hospital Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen
WO1999003828A1 (en) * 1997-07-17 1999-01-28 F.Hoffmann-La Roche Ag Dihomo-seco-cholestanes with two unsaturated bones in the side chain
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781113B2 (en) * 1999-12-21 2005-05-05 Wisconsin Alumni Research Foundation Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
WO2001042205A3 (en) 2002-03-21
EP1233942A2 (de) 2002-08-28
CA2390859A1 (en) 2001-06-14
JP2003516386A (ja) 2003-05-13
WO2001042205A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
US20100160267A1 (en) Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds
AU2001275445B2 (en) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6566352B1 (en) 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US6887860B2 (en) (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US20050143358A1 (en) Methods for reducing body fat using vitamin D compounds
US20060135492A1 (en) Use of 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
KR100835456B1 (ko) 비타민 ｄ 화합물의 투여량 범위를 확장시키는 방법
EP2190422A1 (de) Verfahren zur erweiterung des dosisbereichs von vitamin-d-verbindungen
AU4510001A (en) Treatment of inflammatory bowel disease with vitamin d compounds
CA2556931C (en) Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases
US20050070513A1 (en) Treatment of inflammatory bowel disease with vitamin D compounds
JP4282234B2 (ja) カルセミック活性を持つ１９−ノル−ビタミンｄ３化合物
AU2005225056A1 (en) Treatment of inflammatory bowel disease with Vitamin D compounds
MXPA06003974A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds